Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough leukemia: dasatinib tested after standard therapy fails

NCT ID NCT06055621

Disease control Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing the drug dasatinib alone in adults with acute myeloid leukemia (AML) whose cancer did not respond to the usual combination of venetoclax and azacitidine. The main goal is to see if dasatinib can shrink the leukemia after two months of treatment. About 35 people will take dasatinib daily for up to 3 months, and doctors will check their blood and bone marrow for signs of remission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dasatinib (a targeted cancer drug taken daily by mouth)
What this could lead to
If it works, this could offer a new treatment option for AML patients who have not responded to standard therapy.
What could go wrong
This is a small, early-phase trial with only 35 participants. It may not work for everyone, and dasatinib can cause side effects like fluid retention or heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of AML except Philadelphia chromosome-positive AML (Ph+) and acute promyelocytic leukemia (AML M3) * Age ≥ 18 years * ECOG ≤3 * VEN-AZA refractory defined as no response after two cycles of VEN-AZA whatever the dose and the treatment duration * Signed informed consent form * Affiliation to a social security system, or beneficiary of such a system Exclusion Criteria: * Patient eligible to a targeted therapy having a market authorization * Central nervous system involvement * Heart failure * Liver failure * Kidney failure * Contraindication to DASATINIB * Positive for HIV (detectable viral load), Hepatitis B or C * Pregnant or breastfeeding woman * No efficient contraception for the women of childbearing age * Emergency situation person or not able to express his/her informed consent * Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice) * Inability to undergo the clinical trial medical follow-up for geographical, social or psychological reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Paoli Calmettes

    RECRUITING

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.